BioStock: Elicera receives ATMP classification from EMA

Last week, Elicera Therapeutics announced it has received Advanced Therapy Medicinal Products classification for its lead candidate ELC-100, an oncolytic virus that is currently undergoing a phase I/II trial for the treatment of neuroendocrine tumours. The classification is designed to get promising new cell or gene therapies to market faster, so it gives ELC-100 a welcome regulatory boost.

Read the full article at biostock.se:

https://www.biostock.se/en/elicera-receives-atmp-classification-from-ema/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se